Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Multimodal techniques failed to detect cytomegalovirus in human glioblastoma samples.

Loit MP, Adle-Biassette H, Bouazza S, Mazeron MC, Manivet P, Lehmann-Che J, Teissier N, Mandonnet E, Molina JM.

J Neurovirol. 2018 Nov 5. doi: 10.1007/s13365-018-0683-8. [Epub ahead of print]

PMID:
30397828
2.

Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.

Lehmann-Che J, Bally C, Letouzé E, Berthier C, Yuan H, Jollivet F, Ades L, Cassinat B, Hirsch P, Pigneux A, Mozziconacci MJ, Kogan S, Fenaux P, de Thé H.

Nat Commun. 2018 May 24;9(1):2047. doi: 10.1038/s41467-018-04384-5.

3.

First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.

Lehmann-Che J, Miquel C, Wong J, Callens C, Rouleau E, Quillien V, Lozano N, Cayre A, Lacroix L, Bieche I, Bertheau P, Teixeira L, Llorca FP, Lamy PJ, DE Cremoux P; GFCO GROUP.

Anticancer Res. 2018 May;38(5):2909-2914.

PMID:
29715116
4.

18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.

de Cremoux P, Biard L, Poirot B, Bertheau P, Teixeira L, Lehmann-Che J, Bouhidel FA, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, Groheux D.

Oncotarget. 2018 Mar 27;9(23):16343-16353. doi: 10.18632/oncotarget.24674. eCollection 2018 Mar 27.

5.

Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.

Groheux D, Biard L, Lehmann-Che J, Teixeira L, Bouhidel FA, Poirot B, Bertheau P, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, de Cremoux P.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1279-1288. doi: 10.1007/s00259-018-3998-z. Epub 2018 Apr 4.

PMID:
29616304
6.

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.

DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, Bièche I.

Anticancer Res. 2018 Mar;38(3):1485-1490.

PMID:
29491076
7.

MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels.

Poirot B, Doucet L, Benhenda S, Champ J, Meignin V, Lehmann-Che J.

J Thorac Oncol. 2017 Oct;12(10):1582-1587. doi: 10.1016/j.jtho.2017.07.026. Epub 2017 Aug 2.

8.

Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.

Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, Fontugne J, Georges A, Hennequin C, Lehmann-Che J, Massard C, Millet I, Murez T, Schlageter MH, Rouvière O, Kassab-Chahmi D, Rozet F, Descotes JL, Rébillard X.

Eur Urol Focus. 2017 Mar 7. pii: S2405-4569(17)30065-2. doi: 10.1016/j.euf.2017.02.017. [Epub ahead of print] Review.

PMID:
28753865
9.

[Results of the Massive Open Online Course (MOOC) on cancer diagnosis and evaluation of its impact on the perception of the pathology specialty].

Gardair C, Bousquet G, de Bazelaire C, Lehmann-Che J, de Cremoux P, Tran Van Nhieu J, Battistella M, Sockeel M, Calvani J, Peuchmaur M, Molina T, Gervais J, Moenaert E, Pottier Y, Prévaut L, Sekri K, Bertheau P.

Ann Pathol. 2017 Apr;37(2):144-150. doi: 10.1016/j.annpat.2017.02.001. Epub 2017 Mar 17. French.

PMID:
28318775
10.

Cancer genomics guide clinical practice in personalized medicine.

Lehmann-Che J, Poirot B, Boyer JC, Evrard A.

Therapie. 2017 Sep;72(4):439-451. doi: 10.1016/j.therap.2016.09.015. Epub 2017 Jan 30. Review.

PMID:
28258721
11.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

12.

La génétique somatique des tumeurs solides, un incontournable à l’ère de la médecine de précision.

Lehmann-Che J, Poirot B, Boyer JC, Evrard A.

Therapie. 2017 Apr;72(2):217-230. doi: 10.1016/j.therap.2016.09.009. Epub 2017 Jan 3. French. No abstract available.

PMID:
28162246
13.

[Backstage of a massive open online course (MOOC) on cancer diagnosis].

Gardair C, Bousquet G, Lehmann-Che J, de Bazelaire C, de Cremoux P, Tran Van Nhieu J, Sockeel M, Battistella M, Calvani J, Gervais J, Pottier Y, Prévaut L, Sekri K, Bertheau P.

Ann Pathol. 2016 Oct;36(5):305-311. doi: 10.1016/j.annpat.2016.08.013. Epub 2016 Sep 14. French.

PMID:
27639771
14.

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.

Hamy AS, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretière JM, Matthieu MC, Sigal-Zafrani B, Tembo O, Marty M, Asselain B, Spyratos F, de Cremoux P.

Breast Cancer Res Treat. 2016 Oct;159(3):499-511. doi: 10.1007/s10549-016-3961-2. Epub 2016 Sep 3.

PMID:
27592112
15.

p53 as an Effector or Inhibitor of Therapy Response.

Ablain J, Poirot B, Esnault C, Lehmann-Che J, de Thé H.

Cold Spring Harb Perspect Med. 2015 Dec 4;6(1):a026260. doi: 10.1101/cshperspect.a026260. Review.

16.

Phenotypic analysis of T cells infiltrating colon cancers: Correlations with oncogenetic status.

Chirica M, Le Bourhis L, Lehmann-Che J, Chardiny V, Bouhidel F, Foulboeuf L, Gornet JM, Lourenco N, Dulphy N, Toubert A, Allez M.

Oncoimmunology. 2015 Apr 1;4(8):e1016698. eCollection 2015 Aug.

17.

Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes.

Bally C, Renneville A, Preudhomme C, Legrand M, Adès L, de Thé H, Fenaux P, Lehmann-Che J.

Leuk Res. 2015 Jul 4. pii: S0145-2126(15)30344-1. doi: 10.1016/j.leukres.2015.07.001. [Epub ahead of print]

PMID:
26271412
18.

IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.

Amelot A, De Cremoux P, Quillien V, Polivka M, Adle-Biassette H, Lehmann-Che J, Françoise L, Carpentier AF, George B, Mandonnet E, Froelich S.

PLoS One. 2015 Jul 9;10(7):e0130596. doi: 10.1371/journal.pone.0130596. eCollection 2015.

19.

Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.

Netter J, Lehmann-Che J, Lambert J, Tallet A, Lourenco N, Soliman H, Bertheau P, Pariente B, Chirica M, Pocard M, Allez M, De The H, Gornet JM.

Bull Cancer. 2015 Feb;102(2):117-25. doi: 10.1016/j.bulcan.2014.12.010. Epub 2015 Jan 20.

20.

Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy.

Gauthier H, Douchet G, Lehmann-Che J, Meignin V, Raynaud C, Sabatier P, de Cremoux H, Poirot B, Culine S, Pouessel D, de Cremoux P.

J Thorac Oncol. 2014 Oct;9(10):e78-9. doi: 10.1097/JTO.0000000000000328. No abstract available.

21.

HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.

de Cremoux P, Dalvai M, N'Doye O, Moutahir F, Rolland G, Chouchane-Mlik O, Assayag F, Lehmann-Che J, Kraus-Berthie L, Nicolas A, Lockhart BP, Marangoni E, de Thé H, Depil S, Bystricky K, Decaudin D.

Breast Cancer Res Treat. 2015 Jan;149(1):81-9. doi: 10.1007/s10549-014-3233-y. Epub 2014 Dec 12.

PMID:
25503779
22.

Resistance to therapy in acute promyelocytic leukemia.

Lehmann-Che J, Bally C, de Thé H.

N Engl J Med. 2014 Sep 18;371(12):1170-2. doi: 10.1056/NEJMc1409040. No abstract available.

PMID:
25229938
23.

Concomitant bifocal urothelial carcinoma and breast tumor: second primary cancer or metastatic spread to the breast?

Dumont C, Gauthier H, Vérine J, Lehmann-Che J, de Cremoux P, Pouessel D, Culine S.

Case Rep Oncol Med. 2014;2014:917581. doi: 10.1155/2014/917581. Epub 2014 Aug 4.

24.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P.

Leuk Res. 2014 Jul;38(7):751-5. doi: 10.1016/j.leukres.2014.03.012. Epub 2014 Mar 23.

PMID:
24836762
25.

Orthotopic animal model of pseudomyxoma peritonei: An in vivo model to test anti-angiogenic drug effects.

Dohan A, Lousquy R, Eveno C, Goere D, Broqueres-You D, Kaci R, Lehmann-Che J, Launay JM, Soyer P, Bonnin P, Pocard M.

Am J Pathol. 2014 Jul;184(7):1920-9. doi: 10.1016/j.ajpath.2014.03.004. Epub 2014 May 9.

PMID:
24814606
26.

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.

Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, Cottu PH, Bertheau P, Albiter M, Bouhidel F, Coussy F, Extra JM, Marty M, de Thé H, Espié M.

Br J Cancer. 2014 Mar 18;110(6):1413-9. doi: 10.1038/bjc.2014.81. Epub 2014 Feb 25.

27.

TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.

Győrffy B, Bottai G, Lehmann-Che J, Kéri G, Orfi L, Iwamoto T, Desmedt C, Bianchini G, Turner NC, de Thè H, André F, Sotiriou C, Hortobagyi GN, Di Leo A, Pusztai L, Santarpia L.

Mol Oncol. 2014 May;8(3):508-19. doi: 10.1016/j.molonc.2013.12.018. Epub 2014 Jan 5.

28.

Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial.

Valet F, de Cremoux P, Spyratos F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Delaloge S, Giacchetti S, Brain E, Tembo O, Marty M, Asselain B.

Breast. 2013 Dec;22(6):1052-9. doi: 10.1016/j.breast.2013.08.015. Epub 2013 Oct 2.

PMID:
24095610
29.

p53 in breast cancer subtypes and new insights into response to chemotherapy.

Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H.

Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005. Review.

PMID:
24074787
30.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F.

BMC Cancer. 2013 Jul 22;13:351. doi: 10.1186/1471-2407-13-351.

31.

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.

Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, Habuellelah H, Leman-Detours S, de Roquancourt A, Cahen-Doidy L, Bourstyn E, de Cremoux P, de Bazelaire C, Albiter M, Giacchetti S, Cuvier C, Janin A, Espié M, de Thé H, Bertheau P.

Breast Cancer Res. 2013 May 11;15(3):R37. doi: 10.1186/bcr3421.

32.

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.

Cizkova M, Dujaric ME, Lehmann-Che J, Scott V, Tembo O, Asselain B, Pierga JY, Marty M, de Cremoux P, Spyratos F, Bieche I.

Br J Cancer. 2013 May 14;108(9):1807-9. doi: 10.1038/bjc.2013.164. Epub 2013 Apr 23.

33.

Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.

Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espié M.

Cancer. 2013 Jun 1;119(11):1960-8. doi: 10.1002/cncr.28020. Epub 2013 Mar 15.

34.

Distinct tumor protein p53 mutants in breast cancer subgroups.

Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, Plassa LF, Cottu P, Marty M, André F, Sotiriou C, Pusztai L, de Thé H.

Int J Cancer. 2013 Mar 1;132(5):1227-31. doi: 10.1002/ijc.27767. Epub 2012 Sep 1.

35.

Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.

Janouskova H, Maglott A, Leger DY, Bossert C, Noulet F, Guerin E, Guenot D, Pinel S, Chastagner P, Plenat F, Entz-Werle N, Lehmann-Che J, Godet J, Martin S, Teisinger J, Dontenwill M.

Cancer Res. 2012 Jul 15;72(14):3463-70. doi: 10.1158/0008-5472.CAN-11-4199. Epub 2012 May 16.

36.

Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer.

Spyratos F, Valet F, Bièche I, Scott V, Lehmann-Che J, Asselain B, Tembo O, Marty M, de Cremoux P.

Breast Cancer Res Treat. 2012 Jul;134(1):443-8. doi: 10.1007/s10549-012-2042-4. Epub 2012 Apr 12. No abstract available.

PMID:
22527097
37.

A refined molecular taxonomy of breast cancer.

Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin AL, Feugeas JP, Bièche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de Thé H, Theillet C.

Oncogene. 2012 Mar 1;31(9):1196-206. doi: 10.1038/onc.2011.301. Epub 2011 Jul 25.

38.

Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients.

de Cremoux P, Valet F, Gentien D, Lehmann-Che J, Scott V, Tran-Perennou C, Barbaroux C, Servant N, Vacher S, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Asselain B, Marty M, Spyratos F.

BMC Cancer. 2011 Jun 1;11:215. doi: 10.1186/1471-2407-11-215.

39.

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.

Lehmann-Che J, Amira-Bouhidel F, Turpin E, Antoine M, Soliman H, Legres L, Bocquet C, Bernoud R, Flandre E, Varna M, de Roquancourt A, Plassa LF, Giacchetti S, Espié M, de Bazelaire C, Cahen-Doidy L, Bourstyn E, Janin A, de Thé H, Bertheau P.

Br J Cancer. 2011 May 24;104(11):1739-46. doi: 10.1038/bjc.2011.135. Epub 2011 May 3.

40.

Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.

Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L.

Clin Cancer Res. 2011 Apr 15;17(8):2591-601. doi: 10.1158/1078-0432.CCR-10-1045. Epub 2011 Jan 19.

41.

Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindié E.

Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):426-35. doi: 10.1007/s00259-010-1640-9. Epub 2010 Nov 6.

PMID:
21057787
42.

Hereditary renal cancer syndromes: an update of a systematic review.

Verine J, Pluvinage A, Bousquet G, Lehmann-Che J, de Bazelaire C, Soufir N, Mongiat-Artus P.

Eur Urol. 2010 Nov;58(5):701-10. doi: 10.1016/j.eururo.2010.08.031. Epub 2010 Aug 27. Review.

PMID:
20817385
43.

Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma.

Verine J, Lehmann-Che J, Soliman H, Feugeas JP, Vidal JS, Mongiat-Artus P, Belhadj S, Philippe J, Lesage M, Wittmer E, Chanel S, Couvelard A, Ferlicot S, Rioux-Leclercq N, Vignaud JM, Janin A, Germain S.

PLoS One. 2010 Apr 29;5(4):e10421. doi: 10.1371/journal.pone.0010421.

44.

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.

Lehmann-Che J, André F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espié M, Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, de Thé H.

Oncologist. 2010;15(3):246-52. doi: 10.1634/theoncologist.2009-0243. Epub 2010 Mar 12.

45.

High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.

Manié E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, Gruel N, Lebigot I, Sastre-Garau X, Lidereau R, Remenieras A, Feunteun J, Delattre O, de Thé H, Stoppa-Lyonnet D, Stern MH.

Cancer Res. 2009 Jan 15;69(2):663-71. doi: 10.1158/0008-5472.CAN-08-1560. Erratum in: Cancer Res. 2009 Apr 1;69(7):3240.

46.

p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.

Varna M, Lehmann-Che J, Turpin E, Marangoni E, El-Bouchtaoui M, Jeanne M, Grigoriu C, Ratajczak P, Leboeuf C, Plassa LF, Ferreira I, Poupon MF, Janin A, de Thé H, Bertheau P.

Int J Cancer. 2009 Feb 15;124(4):991-7. doi: 10.1002/ijc.24049.

47.

Chromatin tethering of incoming foamy virus by the structural Gag protein.

Tobaly-Tapiero J, Bittoun P, Lehmann-Che J, Delelis O, Giron ML, de Thé H, Saïb A.

Traffic. 2008 Sep;9(10):1717-27. doi: 10.1111/j.1600-0854.2008.00792.x. Epub 2008 Jul 10.

48.

[Exquisite sensitivity of TP53 mutant breast cancers to dose-dense chemotherapy].

Lehmann-Che J, Turpin E, Bertheau P, Espié M, de Thé H.

Med Sci (Paris). 2007 Nov;23(11):1021-3. French. No abstract available.

49.

Centrosomal pre-integration latency of HIV-1 in quiescent cells.

Zamborlini A, Lehmann-Che J, Clave E, Giron ML, Tobaly-Tapiero J, Roingeard P, Emiliani S, Toubert A, de Thé H, Saïb A.

Retrovirology. 2007 Sep 10;4:63.

50.

Centrosomal latency of incoming foamy viruses in resting cells.

Lehmann-Che J, Renault N, Giron ML, Roingeard P, Clave E, Tobaly-Tapiero J, Bittoun P, Toubert A, de Thé H, Saïb A.

PLoS Pathog. 2007 May 25;3(5):e74.

Supplemental Content

Loading ...
Support Center